Essential Thrombocythemia

Essential Thrombocythemia is a rare blood disorder that affects the body's ability to control the number of platelets, which are tiny cells that help with blood clotting. It involves the bone marrow, where blood cells are made, causing it to produce too many platelets. This excess can lead to problems with blood flow, increasing the risk of blood clots or sometimes causing bleeding. People with this condition may experience symptoms like headaches, dizziness, or unusual bruising. The disorder mainly impacts the circulatory system and can affect overall health by disrupting normal clotting processes.

Essential Thrombocythemia is a chronic myeloproliferative neoplasm characterized by sustained thrombocytosis due to clonal proliferation of megakaryocytes in the bone marrow. It is commonly driven by mutations in genes such as JAK2, CALR, or MPL, leading to constitutive activation of signaling pathways that promote platelet production. The disease is marked by an increased risk of both thrombotic and hemorrhagic complications due to abnormal platelet function and count. Bone marrow biopsy typically shows increased megakaryocyte numbers with characteristic morphology. It is important to distinguish this disorder from reactive thrombocytosis and other myeloproliferative neoplasms. The clinical significance lies in its potential to cause serious vascular events and progression to myelofibrosis or acute leukemia.